Reaction
Colon Cancer Metastatic reporting signals
As of the last recalculation, Colon Cancer Metastatic appears in 1,585 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is REGORAFENIB (PRR 92.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Regorafenib | 78 | 92.7 | 93.4 |
| Panitumumab | 83 | 73.4 | 73.8 |
| Irinotecan Hydrochloride | 40 | 41.9 | 42.0 |
| Trifluridine And Tipiracil | 28 | 34.9 | 35.0 |
| Leucovorin Calcium | 43 | 30.3 | 30.4 |
| Oxaliplatin | 145 | 28.2 | 28.2 |
| Fluorouracil Cream, 0.5% | 127 | 23.7 | 23.7 |
| Fluorouracil | 127 | 23.3 | 23.4 |
| Capecitabine | 140 | 21.9 | 22.0 |
| Bevacizumab | 183 | 21.8 | 21.8 |
| Cetuximab | 38 | 16.3 | 16.3 |
| Prochlorperazine Maleate | 9 | 12.9 | 12.9 |
| Encorafenib | 8 | 10.7 | 10.7 |
| Loperamide Hcl | 10 | 10.3 | 10.3 |
| Loperamide Hydrochloride Oral | 7 | 9.0 | 9.0 |
| Romiplostim | 9 | 7.9 | 7.9 |
| Fosaprepitant Dimeglumine | 8 | 7.7 | 7.7 |
| Fondaparinux Sodium | 4 | 6.5 | 6.5 |
| Ravulizumab | 6 | 5.8 | 5.9 |
| Diroximel Fumarate | 4 | 4.4 | 4.4 |
| Romosozumab-Aqqg | 3 | 2.9 | 2.9 |
| Guselkumab | 6 | 2.2 | 2.2 |
| Pegfilgrastim | 16 | 2.1 | 2.1 |